Bayer Push To Lead OTC Space Relies On Distribution, Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
Bayer expands its distribution, invests in emerging markets and innovation and acquires strategic bolt-ons in an attempt to replace Johnson & Johnson as the largest global OTC business, executives say. Growth areas include gastrointestinal and cough/cold products, but not Rx-to-OTC switch.
You may also be interested in...
In Brief
Bayer buys herbal firm; NBTY notes bright spots, hires international leader; Neptune prepares to rebuild; P&G suit targets CAO’s tooth whiteners; CSPI supports restricting St. John’s wort; Coppertone schools parents; Hillary Clinton will speak at NACDS Total Store Expo.
J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.
Ensuring Leading Position For GSK Consumer Products Touted In Management Shift
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.